vs
Side-by-side financial comparison of Alaunos Therapeutics, Inc. (TCRT) and XBiotech Inc. (XBIT). Click either name above to swap in a different company.
Alaunos Therapeutics, Inc. produced more free cash flow last quarter ($-3.0M vs $-3.5M). Over the past eight quarters, Alaunos Therapeutics, Inc.'s revenue compounded faster (73.2% CAGR vs -100.0%).
Alaunos Therapeutics, Inc. is a clinical-stage biotechnology company that develops novel T cell receptor (TCR) immunotherapies for the treatment of hard-to-treat solid tumors. The firm focuses on advancing precision oncology candidates targeting shared tumor antigens, serving global oncology patient populations via internal R&D and cross-sector partnerships.
XBiotech Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas. It specializes in the research and development of human-derived antibody therapeutics for multiple diseases, including cancer, rheumatological, and infectious diseases.
TCRT vs XBIT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $3.0K | $0 |
| Net Profit | — | $-4.6M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | -40.0% | — |
| Net Profit YoY | -20.5% | -44.7% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.0K | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | $2.0K | — | ||
| Q4 24 | $5.0K | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $4.0K | — | ||
| Q1 24 | $1.0K | — |
| Q4 25 | — | — | ||
| Q3 25 | $-1.2M | — | ||
| Q2 25 | $-1.1M | — | ||
| Q1 25 | $-1.1M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.1M | — | ||
| Q2 24 | $-1.1M | — | ||
| Q1 24 | $-1.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -54600.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -29150.0% | — | ||
| Q1 24 | -174200.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -53650.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -28225.0% | — | ||
| Q1 24 | -168200.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | $-0.55 | — | ||
| Q2 25 | $-0.63 | — | ||
| Q1 25 | $-0.67 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.70 | — | ||
| Q2 24 | $-0.71 | — | ||
| Q1 24 | $-1.05 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4M | $200.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2M | $218.8M |
| Total Assets | $3.0M | $226.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4M | — | ||
| Q3 25 | $1.9M | — | ||
| Q2 25 | $2.9M | — | ||
| Q1 25 | $319.0K | — | ||
| Q4 24 | $1.1M | — | ||
| Q3 24 | $1.7M | — | ||
| Q2 24 | $2.5M | — | ||
| Q1 24 | $4.1M | — |
| Q4 25 | $2.2M | — | ||
| Q3 25 | $2.8M | — | ||
| Q2 25 | $3.7M | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $2.1M | — | ||
| Q3 24 | $2.7M | — | ||
| Q2 24 | $3.8M | — | ||
| Q1 24 | $4.8M | — |
| Q4 25 | $3.0M | — | ||
| Q3 25 | $3.7M | — | ||
| Q2 25 | $4.7M | — | ||
| Q1 25 | $2.1M | — | ||
| Q4 24 | $2.8M | — | ||
| Q3 24 | $3.5M | — | ||
| Q2 24 | $4.7M | — | ||
| Q1 24 | $6.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $-3.4M |
| Free Cash FlowOCF − Capex | $-3.0M | $-3.5M |
| FCF MarginFCF / Revenue | -98900.0% | — |
| Capex IntensityCapex / Revenue | 3266.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-19.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | — | ||
| Q3 25 | $-844.0K | — | ||
| Q2 25 | $-701.0K | — | ||
| Q1 25 | $-772.0K | — | ||
| Q4 24 | $-5.0M | — | ||
| Q3 24 | $-781.0K | — | ||
| Q2 24 | $-1.7M | — | ||
| Q1 24 | $-1.9M | — |
| Q4 25 | $-3.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -98900.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 3266.7% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
